 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company, today announced additional endpoint data from the Companys Phase 2b dose-ranging ASTEROID clinical study of setrusumab BPS-804, an anti-sclerostin antibody, in adults with Type I, III or IV osteogenesis imperfecta OI. 